. 2017 Oct 24;2017:6527306. doi: 10.1155/2017/6527306

Table 2.

Summary of the CD4 T cell responses to the Sp17 peptides by DLBCL patients.

Patients	MHC class II status	Sp17 protein	γ-IFN response to peptides per 50,000 cells
Patients	MHC class II status	Sp17 protein	Sp17(4)	Sp17(5)	Sp17(6)	No peptide	HIV-1	PHA
Significant response
1	DRB1^∗0102,^∗1104	+	42 ± 4	16 ± 2	14 ± 4	12 ± 2	10 ± 4	92 ± 4
2	DRB1^∗0101,^∗0701	+	28 ± 2	8 ± 2	18 ± 2	10 ± 2	6 ± 1	72 ± 12
5	DRB1^∗0301,^∗0401	−	26 ± 4	12 ± 2	14 ± 2	8 ± 2	4 ± 0	108 ± 10
8	DRB1^∗1501,^∗0803	ND	52 ± 4	12 ± 2	14 ± 4	10 ± 2	6 ± 2	78 ± 14
10	DRB1^∗0101	ND	36 ± 4	20 ± 2	10 ± 4	8 ± 2	4 ± 2	86 ± 6
12	DRB1^∗0401,^∗1401	+	50 ± 2	22 ± 4	28 ± 4	16 ± 2	12 ± 4	128 ± 16
14	DRB1^∗1403,^∗0401	ND	38 ± 4	14 ± 2	24 ± 6	8 ± 2	4 ± 2	78 ± 14
18	DRB1^∗0401,^∗0401	+	32 ± 6	18 ± 2	16 ± 4	6 ± 2	10 ± 2	66 ± 12
No significant response
7	DRB1^∗0301,^∗0701	+	18 ± 6	22 ± 2	26 ± 4	14 ± 2	12 ± 2	58 ± 8
9	DRB1^∗0301,^∗1601	−	16 ± 8	32 ± 4	20 ± 4	18 ± 2	14 ± 4	108 ± 10
15	DRB1^∗1301,^∗1101	ND	10 ± 2	12 ± 2	20 ± 4	10 ± 2	14 ± 2	58 ± 8
19	DRB1^∗0401,^∗0901	+	14 ± 2	18 ± 2	6 ± 1	12 ± 2	8 ± 2	50 ± 8
20	DRB1^∗1104,^∗1501	+	24 ± 4	26 ± 2	14 ± 4	14 ± 2	12 ± 2	72 ± 10
21	DRB1^∗0301,^∗1303	+	10 ± 2	14 ± 2	18 ± 2	9 ± 2	8 ± 2	86 ± 6
39	DRB1^∗0701	−	32 ± 4	26 ± 2	14 ± 2	16 ± 2	14 ± 2	112 ± 16
43	DRB1^∗0101,^∗1101	−	24 ± 4	32 ± 2	28 ± 2	18 ± 4	20 ± 2	98 ± 12
48	DRB1^∗0101,^∗0405	−	28 ± 4	10 ± 2	18 ± 2	18 ± 4	14 ± 2	98 ± 8

DLBCL(dn): de novo diffuse large B cell lymphoma; DLBCL(t): diffuse large B cell lymphoma transformed; TCR: T cell rich B cell lymphoma. The results +/− are from triplicate ELISPOT cultures. The SD was calculated using standard techniques. Significant γ-IFN responses are highlighted in bold. ND, not determined.